Previous studies indicate that capecitabine exhibits less favorable tolerability among patients with colorectal cancer in the United States, with women facing an increased risk for toxicity.

SHR-1701 plus CAPOX reduced chemotherapy-induced myelosuppression in HER2-negative gastric/GEJ adenocarcinoma patients, showing fewer treatment delays and dose reductions. The trial demonstrated lower ...

Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity. This is an ASCO Meeting Abstract from the ...

Six months of chemotherapy in low-risk stage 3 colorectal cancer patients increases neuropathy compared to three months. IDEA collaboration found similar survival outcomes between three and six months ...

"These latest datasets further solidify the evidence affirming the efficacy that Osemitamab (TST001) plus CAPOX chemotherapy can provide as a first-line treatment for advanced gastric and ...